Ä«Å×°í¸®
|
Cytokines & Growth Factor
|
CAT.NO
|
LGP-12-022
|
PRODUCT
|
IL-36¥â(183a.a.), Mouse (Murine Interleukin-36 beta, 183aa)
|
SIZE
|
10ug, 100ug, 250ug
|
PRICE
|
KRW 285,000, 1,522,000, 2,622,000
|
Technical Parameters
Synonyms |
FIL1 eta, IL-1 eta, IL-1F8, IL-1H2 |
Accession |
Q9D6Z6 |
GeneID |
69677 |
Source |
Escherichia coli. |
Molecular Weight |
Approximately 20.9 kDa, a single non-glycosylated polypeptide chain containing 183 amino acids. |
Quantity |
10µg/100µg/250µg |
AA Sequence |
MMAFPPQSCV HVLPPKSIQM WEPNHNTMHG SSQSPRNYRV HDSQQMVWVL TGNTLTAVPA SNNVKPVILS LIACRDTEFQ DVKKGNLVFL GIKNRNLCFC CVEMEGKPTL QLKEVDIMNL YKERKAQKAF LFYHGIEGST SVFQSVLYPG WFIATSSIER QTIILTHQRG KLVNTNFYIE SEK |
Purity |
> 95 % by SDS-PAGE and HPLC analyses. |
Biological Activity |
Fully biologically active when compared to standard. The specific activity determined by its ability in a functional ELISA. Immobilized rMuIL-36¥â at 1 µg/mL can bind recombinant murine IL-1 Rrp2 with a range of 0.15-5 µg/mL. |
Physical Appearance |
Sterile Filtered White lyophilized (freeze-dried) powder. |
Formulation |
Lyophilized from a 0.2 ¥ìm filtered concentrated solution in 20 mM Tris, 300 mM NaCl, pH 8.0, 5 % trehalose. |
Endotoxin |
Less than 1 EU/¥ìg of rMuIL-36¥â, 183a.a. as determined by LAL method. |
Reconstitution |
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/ml. Stock solutions should be apportioned into working aliquots and stored at ¡Â -20 ¡ÆC. Further dilutions should be made in appropriate buffered solutions. |
Stability & Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. - 12 months from date of receipt, -20 to -70 ¡ÆC as supplied. - 1 month, 2 to 8 ¡ÆC under sterile conditions after reconstitution. - 3 months, -20 to -70 ¡ÆC under sterile conditions after reconstitution. |
Usage |
This material is offered by Korea Lugen Sci for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE. |
SDS-PAGE |
|
Reference |
1. Nicklin MJ, Barton JL, Nguyen M, et al. 2002. Genomics. 79:718-25. 2. Dinarello C, Arend W, Sims J, et al. 2010. Nat Immunol. 11:973. 3. Magne D, Palmer G, Barton JL, et al. 2006. Arthritis Res Ther. 8:R80. 4. van Asseldonk EJ, Stienstra R, Koenen TB, et al. 2010. Obesity (Silver Spring). 18:2234-6. 5. Johnston A, Xing X, Guzman AM, et al. 2011. J Immunol. 186:2613-22. |
Background |
Interleukin-36 (IL-36) is a pro-inflammatory cytokine which plays an important role in the pathophysiology of several diseases. IL-36¥á, IL-36¥â, and IL-36¥ã (formerly IL-1F6, IL-1F8, and IL-1F9) are IL-1 family members that signal through the IL-1 receptor family members IL-1Rrp2 (IL-1RL2) and IL-1RAcP. IL-36 beta is reported to be expressed at higher levels in psoriatic plaques than in symptomless psoriatic skin or healthy control skin and it can stimulate production of interleukin-6 and interleukin-8 in synovial fibrobasts, articular chondrocytes and mature adipocytes. It beta has two isoforms. IL-36¥â isoform 2 contains one potential N-linked glycosylation site in its C-terminus, while IL -36¥â isoform 1 lacks potential N-linked glycosylation sites and four of the conserved ¥â-strands. Within the IL-1 family, IL-36¥â/IL-1F8 shares 30 %, 32 %, 37 %, 46 %, 34 %, 45 % and 28 % a.a. sequence identity with IL-1 ra, IL-1¥â, IL-36Ra/IL-1F5, IL-36¥á/IL-1F6, IL-37/IL-1F7, IL-36¥ã/IL-1F9 and IL-1F10, respectively. |
|
÷ºÎÆÄÀÏ
|
|
|
|
|